DOCSLIB.ORG

Effectiveness of Intranasal Live Attenuated Influenza Vaccine Against All-Cause Acute Otitis Media in Children Heikkinen Et Al Terho Heikkinen, MD, Phd,* Stan L

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Effectiveness of Intranasal Live Attenuated Influenza Vaccine Against All-Cause Acute Otitis Media in Children Heikkinen Et Al Terho Heikkinen, MD, Phd,* Stan L Mary INF VACCINE REPORTS 203098 LAIV and Acute Otitis Media Effectiveness of Intranasal Live Attenuated Influenza Vaccine Against All-cause Acute Otitis Media in Children Heikkinen et al Terho Heikkinen, MD, PhD,* Stan L. Block, MD,† Seth L. Toback, MD,‡ Xionghua Wu, PhD,‡ and Christopher S. Ambrose, MD‡ cute otitis media (AOM) remains the most common bacterial Background: Acute otitis media (AOM) is a frequent complication of influ- infection and the most frequent reason for antibiotic treatment enza in children, and influenza vaccination helps protect against influenza- A Pediatr Infect Dis J in infants and young children. Although the incidence of AOM associated AOM. A live attenuated influenza vaccine (LAIV) approved for peaks around the age of 1 year, the rates of AOM are substantial eligible children aged ≥2 years for the prevention of influenza also effec- in older children.1,2 The high prevalence of antimicrobial resistance tively reduces influenza-associated AOM. However, the annual effective- among common bacteria causing AOM has substantially compli- Lippincott Williams & Wilkins ness of LAIV against all-cause AOM is unknown. cated the management of AOM, and efforts to reduce the use of Methods: AOM rates in children aged 6–83 months from 6 randomized, antibiotics for this disease are being assessed. As a consequence, placebo-controlled trials and 2 randomized, inactivated influenza vaccine- prevention of AOM through vaccination is an important area of controlled trials were pooled and analyzed. To enable comparison with Hagerstown, MD research.3,4 studies of AOM prevention by pneumococcal conjugate vaccines, 12-month Pneumococcal conjugate vaccines (PCVs) are currently effectiveness was calculated assuming that LAIV had no effect outside of used in most developed countries to prevent severe invasive pneu- influenza seasons. XXX mococcal illnesses in children. Although these 7- to 13-valent vac- Results: During influenza seasons, LAIV efficacy compared with placebo cines are very effective against invasive pneumococcal infections, against all-cause AOM in children aged 6–71 months (N = 9497) was they have also shown some efficacy against pneumococcal AOM. 12.4% (95% confidence interval [CI]: 2.0%, 21.6%) in year 1. In year 2, In a large clinical trial in Finland, the efficacy of the 7-valent PCV the efficacy in children aged 18–83 months (N = 4142) was 6.2% (95% CI: (PCV7) was 34% against AOM caused by any pneumococci in chil- −12.4%, 21.7%). Compared with inactivated influenza vaccine, the efficacy dren followed up to 24 months of age.5 However, because other bac- of LAIV in children aged 6–71 months (N = 9901) against febrile all-cause teria and viruses account for the majority of all AOM cases, PCV7 AOM was 9.7% (95% CI: −2.1%, 20.1%). The estimated 12-month effec- was able to reduce the annual incidence of all-cause AOM by 6%. tiveness of LAIV compared with placebo against all-cause AOM was 7.5% Similar results were obtained in the United States, where PCV7 was (95% CI: −2.4%, 16.2%). shown to reduce the rates of all-cause AOM episodes by 6.6% and Conclusions: LAIV reduced the incidence of all-cause AOM compared office visits by 7.8% in children aged 3–42 months.1 Higher reduc- with placebo in children. The estimated 12-month effectiveness of LAIV 2013 tions in all-cause AOM due to PCV7 have been reported6,7 in non- was comparable with 7-valent pneumococcal conjugate vaccine. The effects randomized studies that are influenced by herd protection, potential of the vaccines will overlap somewhat; however, because pneumococcal temporal confounding from more stringent criteria for diagnosing conjugate vaccines only prevent a fraction of all pneumococcal AOM and AOM and increasing use of influenza vaccines in US children. influenza-associated AOM can be caused by other pathogens, LAIV could The key role of respiratory viruses in the etiology and patho- further reduce the incidence of AOM in children. genesis of AOM is well established.3 Influenza viruses are known Key Words: acute otitis media, live attenuated influenza vaccine, trivalent to predispose a child to AOM.2,8–13 In a large prospective study of Copyright © 2013 by Lippincott Williams & Wilkins inactivated influenza vaccine respiratory infections in children, AOM developed as a complica- tion of influenza in 40% of children aged <3 years and in 20% (Pediatr Infect Dis J 2013;32: 669–674) of children aged 3–6 years.12 Several clinical studies have demon- 00 strated that influenza-associated AOM can be effectively prevented by influenza vaccination.9,14–16 However, because influenza vaccine cannot exert its effect outside of the influenza season, the pub- lic health impact of influenza vaccination in reducing the overall 00 Accepted for publication December 19, 2012. annual incidence of AOM remains unknown. From the *Department of Pediatrics, University of Turku and Turku University Hospital, Turku, Finland; †Kentucky Pediatric and Adult Research, Bard- An intranasally administered, Ann Arbor strain live attenu- 0891-3668 stown, KY; and ‡MedImmune, Gaithersburg, MD. ated influenza vaccine (LAIV) is approved for eligible children Seth L. Toback, MD is currently at Gilead Sciences, Inc. Seattle, WA. aged ≥2 years. We have previously shown that the efficacy of LAIV TH and SLB have served as consultants for MedImmune, LLC (Gaithersburg, against influenza-associated AOM was 85% compared with pla- MD). SLT was an employee of MedImmune at the time of study and draft- cebo and 54% compared with inactivated influenza vaccine (IIV).17 10.1097/INF.0b013e3182840fe7 ing of the manuscript. XW and CSA are employees of MedImmune. This research was funded by MedImmune. Employees of MedImmune worked The aim of this study was to determine the effectiveness of LAIV collaboratively with the investigators in the design of the study, in analysis against all-cause AOM in children during influenza seasons, total and interpretation of the data, and reviewed and approved the manuscript. study surveillance periods and throughout an entire year. The Pediatric Infectious Disease Journal TH and SLB were not paid for their work on this manuscript. Editorial assis- tance in formatting the manuscript for submission was provided by Susan E. Myers, MSc, and Gerard P. Johnson, PhD, of Complete Healthcare Commu- MATERIALS AND METHODS nications, Inc. (Chadds Ford, PA) and funded by MedImmune. The authors 32 have no other funding or conflicts of interest to disclose. Eight randomized studies were identified in which LAIV Address for correspondence: Terho Heikkinen, MD, PhD, Department of Pedi- efficacy against AOM was a prespecified secondary endpoint. atrics, Turku University Hospital, FI-20520 Turku, Finland. E-mail: terho. These studies were conducted in the United States, Europe and [email protected]. Asia (Table 1). These studies have been described previously as 6 Copyright © 2012 by Lippincott Williams & Wilkins ISSN: 0891-3668/13/3206-669 individual studies and in an integrated analysis of influenza- DOI: 10.1097/INF.0b013e3182840fe7 associated AOM incidence.17–26 Six trials compared LAIV with June The Pediatric Infectious Disease Journal • Volume 32, Number 6, June 2013 www.pidj.com | 669 2013 Heikkinen et al The Pediatric Infectious Disease Journal • Volume 32, Number 6, June 2013 TABLE 1. Live Attenuated Influenza Vaccine Studies Measuring Efficacy Against AOM Study Number Age Range, mo LAIV, N Control, N Location Placebo-controlled studies Study 1, year 118 12–35 1653 1111 Asia Study 1, year 218 24–47 771 494 Asia Study 2, year 119 6–35 951 665 Europe Study 2, year 219 18–47 640 450 Europe Study 3, year 120 6–35 944 942 Multinational Study 3, year 220 18–47 338 342 Multinational Study 421 6–35 525 516 Asia Study 522 11–23 765 385 Multinational Study 6, year 123 15–71 854 417 United States Study 6, year 224 27–83 747 362 United States IIV-controlled studies Study 725 6–71 1050 1035 Europe Study 826 6–59 3916 3935 Multinational placebo, and 2 trials compared LAIV with IIV. Data on episodes of analysis. Therefore, pooled analyses were performed separately for AOM due to any cause were extracted by treatment group from all years 1 and 2. An estimate of efficacy against all-cause AOM epi- studies for the per-protocol population. The analyses included only sodes was calculated using the Andersen-Gill method with robust those children who were fully vaccinated (2 doses if previously sandwich covariance estimate of Cox proportional hazards model unvaccinated, 1 dose if previously vaccinated). If multiple potencies with treatment as the only effect. The efficacy was calculated as (1 of LAIV were studied,21 only data from the approved dose potency – hazard ratio) × 100. (106.5–7.5 fluorescent focus units/mL) were included in the analysis. All-cause AOM was defined as AOM due to any cause in Projected 12-Month Effectiveness Estimate study subjects, regardless of viral culture results. As in the study To estimate the annual impact of LAIV on all-cause AOM, of PCV7 by Eskola et al,5 an AOM episode was considered as a AOM rates were projected for months outside of the study surveil- new episode if it occurred at least 30 days after the previous AOM lance periods. To make comparisons with the randomized, placebo- episode. In 5 of the 6 placebo-controlled studies and in the IIV- controlled studies of PCV7 that were conducted in the United controlled study by Ashkenazi et al,25 AOM was defined using the States1,27 and Europe,5 only data from subjects in the United States criteria used by Eskola et al5: by the demonstration of a visually and Europe in placebo-controlled studies were used. Actual study abnormal tympanic membrane (with regard to color, position and/ data were used for AOM rates for months during the study surveil- or mobility) suggesting effusion in the middle ear, concomitantly lance periods.
Load more

Recommended publications
  • Acute Otitis Media, Acute Bacterial Sinusitis, and Acute Bacterial Rhinosinusitis
    Acute Otitis Media, Acute Bacterial Sinusitis, and Acute Bacterial Rhinosinusitis This guideline, developed by Larry Simmons, MD, in collaboration with the ANGELS team, on October 3, 2013, is a significantly revised version of the Recurrent Otitis Media guideline by Bryan Burke, MD, and includes the most recent information for acute otitis media, acute bacterial sinusitis, and acute bacterial rhinosinusitis. Last reviewed by Larry Simmons, MD on July 5, 2016. Preface As the risk factors for the development of acute otitis media (AOM) and acute bacterial sinusitis (ABS)/ acute bacterial rhinosinusitis (ABRS) are similar, the bacterial pathogens are essentially the same for both AOM and ABS/ABRS, and since the antimicrobial treatments are similar, the following guideline is based, unless otherwise referenced, on recently published evidenced-based guidelines by the American Academy of Pediatrics (AAP) for AOM,1,2 and by the Infectious Diseases Society of 3 America (IDSA) for ABRS. This guideline applies to children 6 months to 12 years of age and otherwise healthy children without pressure equalizer (PE) tubes, immune deficiencies, cochlear implants, or anatomic abnormalities including cleft palate, craniofacial anomalies, and Down syndrome. However, the IDSA ABRS guideline includes recommendations for children and adult patients. Key Points Acute otitis media (AOM) is characterized by a bulging tympanic membrane (TM) + middle-ear effusion. Antibiotic treatment is indicated in children ≥6 months of age with severe AOM, children 6-23 months of age with mild signs/symptoms of bilateral AOM. In children 6-23 months of age with non-severe unilateral AOM, and in children ≥24 months of age with bilateral or unilateral 1 AOM who have mild pain and low fever <39°C/102.2°F, either antibiotic treatment or observation is appropriate.
    [Show full text]
  • Rate of Concurrent Otitis Media in Upper Respiratory Tract Infections with Specific Viruses
    ORIGINAL ARTICLE Rate of Concurrent Otitis Media in Upper Respiratory Tract Infections With Specific Viruses Cuneyt M. Alper, MD; Birgit Winther, MD, PhD; Ellen M. Mandel, MD; J. Owen Hendley, MD; William J. Doyle, PhD Objective: To estimate the coincidence of new otitis me- Results: A total of 176 children (81%) had isolated PCR dia (OM) for first nasopharyngeal detections of the more detection of at least 1 virus. The OM coincidence rates common viruses by polymerase chain reaction (PCR). were 62 of 144 (44%) for rhinovirus, 15 of 27 (56%) for New OM episodes are usually coincident with a viral up- respiratory syncytial virus, 8 of 11 (73%) and 1 of 5 (20%) per respiratory tract infection (vURTI), but there are con- for influenza A and B, respectively, 6 of 12 (50%) for ad- flicting data regarding the association between specific enovirus, 7 of 18 (39%) for coronavirus, and 4 of 11 (36%) viruses and OM. for parainfluenza virus detections (P=.37). For rhinovi- rus, new OM occurred in 50% of children with and 32% Design: Longitudinal (October-March), prospective fol- without a concurrent CLI (P=.15), and OM risk was pre- low-up of children for coldlike illness (CLI) by diary, middle dicted by OM and breastfeeding histories and by daily ear status by pneumatic otoscopy, and vURTI by PCR. environment outside the home. Setting: Academic medical centers. Conclusions: New OM was associated with nasopha- ryngeal detection of all assayed viruses irrespective of Participants: A total of 102 families with at least 2 chil- the presence or absence of a concurrent CLI.
    [Show full text]
  • Otovent Nasal Balloon for Otitis Media with Effusion
    pat hways Otovent nasal balloon for otitis media with effusion Medtech innovation briefing Published: 15 March 2016 www.nice.org.uk/guidance/mib59 Summary Otovent is a balloon device designed to relieve the symptoms of otitis media with effusion, commonly known as glue ear. An Otovent kit consists of a nose piece and 5 latex balloons that are inflated yb blowing through the nose. Four randomised controlled trials, all in children, have shown that using the device causes significant improvements, compared with standard care, in middle ear function; 1 of the trials also reported a significant reduction in the need for entilationv tube (grommet) insertion surgery. Outcomes varied by compliance with (that is, adherence to) treatment, and standard care was not consistently described. The Otovent kit is available to buy or can be provided on a NHS prescription. The recommended retail price is £7.84 including VAT and the current Drug Tariff price is £4.90 excluding VAT. No additional consumables are needed. © NICE 2020. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- Page 1 of conditions#notice-of-rights). 24 Otovent nasal balloon for otitis media with effusion (MIB59) Product summary and likely place in Effectiveness and safety therapy • No relevant evidence was found for the use of • Otovent is designed to help open the Otovent in adults. Eustachian tubes and equalise the air pressure in the middle ear. • Four randomised controlled trials involving a total of 565 children showed statistically significant • The device can be used in people improvements in middle ear function with with Eustachian tube dysfunction Otovent compared with standard care, as associated with glue ear (otitis determined by tympanometry and pneumatic media with effusion), or after flying, otometry.
    [Show full text]
  • Bacterial Sinusitis and Otitis Media Following Inffuenza Virus Infection In
    INFECTION AND IMMUNITY, May 2006, p. 2562–2567 Vol. 74, No. 5 0019-9567/06/$08.00ϩ0 doi:10.1128/IAI.74.5.2562–2567.2006 Copyright © 2006, American Society for Microbiology. All Rights Reserved. Bacterial Sinusitis and Otitis Media following Influenza Virus Infection in Ferrets Ville T. Peltola,1 Kelli L. Boyd,2 Julie L. McAuley,1 Jerold E. Rehg,3 and Jonathan A. McCullers1* Departments of Infectious Diseases1 and Pathology3 and Animal Resources Center,2 St. Jude Children’s Research Hospital, Memphis, Tennessee Received 17 August 2005/Returned for modification 27 September 2005/Accepted 1 February 2006 Streptococcus pneumoniae is the leading cause of otitis media, sinusitis, and pneumonia. Many of these infections result from antecedent influenza virus infections. In this study we sought to determine whether the frequency and character of secondary pneumococcal infections differed depending on the strain of influenza virus that preceded bacterial challenge. In young ferrets infected with influenza virus and then challenged with pneumococcus, influenza viruses of any subtype increased bacterial colonization of the nasopharynx. Nine out of 10 ferrets infected with H3N2 subtype influenza A viruses developed either sinusitis or otitis media, while only 1 out of 11 ferrets infected with either an H1N1 influenza A virus or an influenza B virus did so. These data may partially explain why bacterial complication rates are higher during seasons when H3N2 viruses predominate. This animal model will be useful for further study of the mechanisms that underlie viral-bacterial synergism. Influenza virus infection predisposes children to secondary was itself replaced in 1968 with a strain carrying a new H3 HA bacterial infections such as sinusitis, otitis media, and pneu- but the same N2 NA (subtype H3N2).
    [Show full text]
  • Pneumonia and Otitis Media
    put together by Alex Yartsev: Sorry if i used your images or data and forgot to reference you. Tell me who you are. [email protected] Pneumonia and Otitis Media Detailed History of Presenting Illness (HPI) PNEUMONIA - Fever - Rigors ( chills ) - Cough - Wheeze - Tachypnoea - Pleuritic chest pain OTITIS MEDIA - Pain in Ear - Exudate from ear (if tympanic membrane integrity is compromised) - Low-grade fever - Poor appetite - Irritablily - Usually v. young (<2 y.o) Differential Diagnoses (DDx) PNEUMONIA DD X Bacterial or Viral Pneumonia: !! SUDDEN ONSET = BACTERIAL!! !! GRADUAL ONSET = VIRAL!! - Recurrent Lower Respiratory Tract Infection due to immune suppression - Tuberculosis - Pertussis (whooping Cough , respective of age group) NON-INFECTIOUS CAUSES THAT CAN PRESENT AS PNEUMONIA: - Congestive Heart Failure, - Wegener's granulomatosis (diffuse connective - pulmonary infiltrates with eosinophilia, tissue disease, aetiology unknown) - pulmonary hemorrhage, - collagen-vascular disorders - Goodpasture's syndrome, (hypersensitivity, basement - (including rheumatoid lung disease, SLE, membrane antibodies) scleroderma), - pulmonary embolism, - amyloidosis, - neoplastic disease, - sarcoidosis, - radiation injury, - interstitial pneumonitis (e.g., farmers, bird - inhalation injury, breeders), - pulmonary contusion, - drug reactions (e.g., hydrochlorothiazide, - bronchiolitis obliterans with organizing pneumonia asbestos, silicosis, bleomycin etc.) (BOOP), OTITIS MEDIA DD X - pharyngitis, - dental disease, - temporal mandibular joint
    [Show full text]
  • Otitis Media: Diagnosis and Treatment KATHRYN M
    This is a corrected version of the article that appeared in print. Otitis Media: Diagnosis and Treatment KATHRYN M. HARMES, MD; R. ALEXANDER BLACKWOOD, MD, PhD; HEATHER L. BURROWS, MD, PhD; JAMES M. COOKE, MD; R. VAN HARRISON, PhD; and PETER P. PASSAMANI, MD University of Michigan Medical School, Ann Arbor, Michigan Acute otitis media is diagnosed in patients with acute onset, presence of middle ear effusion, physical evidence of middle ear inflammation, and symptoms such as pain, irritability, or fever. Acute otitis media is usually a complication of eustachian tube dysfunction that occurs dur- ing a viral upper respiratory tract infection. Streptococcus pneumoniae, Haemophilus influen- zae, and Moraxella catarrhalis are the most common organisms isolated from middle ear fluid. Management of acute otitis media should begin with adequate analgesia. Antibiotic therapy can be deferred in children two years or older with mild symptoms. High-dose amoxicillin (80 to 90 mg per kg per day) is the antibiotic of choice for treating acute otitis media in patients who are not allergic to penicillin. Children with persistent symptoms despite 48 to 72 hours of anti- biotic therapy should be reexamined, and a second-line agent, such as amoxicillin/clavulanate, should be used if appropriate. Otitis media with effusion is defined as middle ear effusion in the absence of acute symptoms. Antibiotics, decongestants, or nasal steroids do not hasten the clearance of middle ear fluid and are not recommended. Children with evidence of anatomic damage, hearing loss, or language delay should be referred to an otolaryngologist. (Am Fam Physician. 2013;88(7):435-440.
    [Show full text]
  • ENT Infections: Otitis Media and Sinusitis in Children
    3/25/2019 Disclosures ENT infections: Consultant/ CareFusion-Scientific Advisory Board Speakers bureaus Otitis media and sinusitis in Research funding MedImmune, Melinta children Kari Simonsen, MD Stock No Disclosures Professor of Pediatrics, ownership/Corporate Division of Pediatric Infectious Diseases boards-employment Off-label uses No Disclosures Objectives: Otitis Media-Diagnosis • Discuss the AAP Guidelines for Diagnosis and Management • Key Guideline: Diagnosis and Management of of Acute Otitis Media Acute Otitis Media; Pediatrics 2013;131;e964; • Discuss the AAP Guidelines for the Diagnosis and – http://pediatrics.aappublications.org/content/ Management of Acute Bacterial Sinusitis in Children 131/3/e964.full.pdf+html • Be aware of potential warning signs for complications in these conditions! – https://www.aappublications.org/news/2018/0 6/26/idsnapshot062618 Otitis Media-Diagnosis Otitis Media- Diagnosis Physical Exam findings • Clinical Manifestations – Erythema and bulging of tympanic membrane – Fever (may or may not be present) – Air‐fluid level behind the tympanic membrane – Otalgia – Decreased tympanic membrane mobility on – Irritability pneumatic otoscopy • Frequent associated with – Otorrhea antecedent/concurrent viral URI 1 3/25/2019 How well do we perform Otitis Media-Diagnosis and teach otoscopy? Key Action Statements from the 2013 AAP /AAFP • Training in physical examination begins in medical updated guidelines regarding making the school, pediatrics clerkship may provide the best diagnosis correctly: opportunity
    [Show full text]
  • Otitis Media
    Otitis media What is otitis media? What are the signs of otitis media? Otitis media (oh-tite -iss mee -dee-ah, or • earache, especially at night middle ear infection) is one of the most • pulling hard or poking at the ear common childhood illnesses. It is caused by • shaking the head a virus or bacteria that travels from the nose • runny nose, cough, or sore throat or throat along the eustachian tube to the • crabby, more crying than usual middle ear. Ear infections do not spread to • not eating or drinking as usual: baby others. may pull away from the breast or bottle when drinking ear canal • not hearing well, or ear feels “plugged” • fluid draining from the ear What is the treatment? eustachian tube eardrum Acetaminophen (Tylenol ® or another brand) middle ear or ibuprofen (such as Advil ®) can be given for comfort. Sometimes a warm (not hot) washcloth or heating pad over the ear helps it feel better. Otitis media can also occur if the eardrum gets a hole in it—from injury or repeated Your health care provider may prescribe an infections. antibiotic to kill the bacteria causing the infections. Give the medicine for the A baby who lies down while drinking from a prescribed amount of time, even if your bottle may get more ear infections: The child feels better, to be sure all the infection formula, milk, or juice can go up through the is gone. ( Note: If the infection is caused by eustachian tubes, irritating or swelling them. a virus, antibiotics may not help.) The sugar in these liquids causes germs to grow.
    [Show full text]
  • Bronchiolitis – Medical Management
    Evidence Based Clinical Practice Guideline For Infants with Bronchiolitis Guideline 1 Health Policy & Clinical Effectiveness Program Introduction References in parentheses ( ). Evidence strengths in [ ]. (See last page for definitions.) Evidence Based Clinical Practice Guideline Bronchiolitis is an acute inflammatory disease of the lower respiratory tract, resulting from obstruction of For medical management of small airways. It is initiated by infection of the upper Bronchiolitis respiratory tract by any one of a number of seasonal in infants less than 1 year of age viruses , the most common of which is respiratory presenting with a first time episodea syncytial virus (RSV) (Williams 2004 [C], Andreoletti 2000 [C], Original Publication Date: December 6, 1996 Hall 2001 [S], Stark 1991 [S]). Revision Publication Dates: November 28, 2001 There is considerable confusion and variability with August 15, 2005 respect to the clinical management of infants with New search May, 2006 (see Development Process section) bronchiolitis. Typical bronchiolitis in infants is a self- limited disease, usually due to an acute viral infection that is little modified by aggressive evaluations, use of Target Population antibiotics or other therapies. The median duration of illness for children < 24 months with bronchiolitis is 12 Inclusion: Intended primarily for use in children: days; after 21 days approximately 18% will remain ill, • age less than 12 completed months and presenting for and after 28 days 9% will remain ill (Swingler 2000 [C]). the first time with bronchiolitis typical in presentation Most infants who contract bronchiolitis recover without and clinical course sequelae; however, up to 40% may have subsequent wheezing episodes through five years of age and Exclusion: Not intended for use in children: approximately ten percent will have wheezing episodes with a history of cystic fibrosis (CF) • after age five (van Woensel 2000 [B]).
    [Show full text]
  • Pneumococcus: Questions and Answers Information About the Disease and Vaccines
    Pneumococcus: Questions and Answers information about the disease and vaccines What causes pneumococcal disease? Pneumococci cause 50% of all cases of bacterial men- Pneumococcal disease is caused by the bacterium ingitis (infection of the covering of the brain or spinal Streptococcus pneumoniae, also called pneumococcus. cord) in the United States. There are an estimated There are more than 90 subtypes. Most subtypes can 2,000 cases of pneumococcal meningitis each year. cause disease, but only a few produce the majority of Symptoms may include headache, tiredness, vomiting, invasive pneumococcal infections. The 10 most common irritability, fever, seizures, and coma. The case-fatality subtypes cause 62% of invasive disease worldwide. rate of pneumococcal meningitis is 8% among chil- dren and 22% among adults. From 5% to 90% of nor- How does pneumococcal disease spread? mal healthy adults, depending on the population and setting, may have pneumococci in their nose or throat The disease is spread from person to person by drop- (i.e., they might be carriers.) Permanent neurologic lets in the air. The pneumococci bacteria are common damage is common among survivors. People with a inhabitants of the human respiratory tract. cochlear implant appear to be at increased risk of What diseases can pneumococci bacteria cause? pneumococcal meningitis. With the decline of invasive Hib disease, pneumococci has become the leading There are three major conditions caused by pneumo- cause of bacterial meningitis among children younger cocci: pneumonia, bacteremia, and meningitis. They than 5 years of age in the United States. are all caused by infection with the same bacteria, but have different symptoms.
    [Show full text]
  • AAP-Bronchiolitis-Guidelines.Pdf
    Guidance for the Clinician in Rendering Pediatric Care CLINICAL PRACTICE GUIDELINE Clinical Practice Guideline: The Diagnosis, Management, and Prevention of Bronchiolitis Shawn L. Ralston, MD, FAAP, Allan S. Lieberthal, MD, FAAP, abstract H. Cody Meissner, MD, FAAP, Brian K. Alverson, MD, FAAP, Jill E. This guideline is a revision of the clinical practice guideline, “Diagnosis Baley, MD, FAAP, Anne M. Gadomski, MD, MPH, FAAP, ” David W. Johnson, MD, FAAP, Michael J. Light, MD, FAAP, and Management of Bronchiolitis, published by the American Academy Nizar F. Maraqa, MD, FAAP, Eneida A. Mendonca, MD, PhD, of Pediatrics in 2006. The guideline applies to children from 1 through FAAP, FACMI, Kieran J. Phelan, MD, MSc, Joseph J. Zorc, MD, 23 months of age. Other exclusions are noted. Each key action state- MSCE, FAAP, Danette Stanko-Lopp, MA, MPH, Mark A. ment indicates level of evidence, benefit-harm relationship, and level Brown, MD, Ian Nathanson, MD, FAAP, Elizabeth of recommendation. Key action statements are as follows: Pediatrics Rosenblum, MD, Stephen Sayles III, MD, FACEP, and Sinsi Hernandez-Cancio, JD 2014;134:e1474–e1502 KEY WORDS bronchiolitis, infants, children, respiratory syncytial virus, evidence-based, guideline DIAGNOSIS ABBREVIATIONS AAP—American Academy of Pediatrics 1a. Clinicians should diagnose bronchiolitis and assess disease se- AOM—acute otitis media verity on the basis of history and physical examination (Evidence CI—confidence interval Quality: B; Recommendation Strength: Strong Recommendation). ED—emergency department
    [Show full text]
  • The Clinical Course of Bronchiolitis Associated with Acute Otitis Media
    Arch Dis Child 2000;83:317–319 317 The clinical course of bronchiolitis associated with Arch Dis Child: first published as 10.1136/adc.83.4.317 on 1 October 2000. Downloaded from acute otitis media Gila Shazberg, Shoshana Revel-Vilk, David Shoseyov, Anat Ben-Ami, Aharon Klar, Haggit Hurvitz Abstract has not, to the best of our knowledge, been Background—Acute otitis media (AOM) systematically studied. The aim of the present is the most common bacterial co-infection study was to investigate whether AOM, bacte- of viral bronchiolitis. rial or viral, influences the clinical course of Aims—To evaluate the influence of AOM bronchiolitis. on the clinical course of bronchiolitis. Subjects—150 children younger than 24 months old, diagnosed with bronchiolitis, hospitalised between December 1997 and Methods May 1999. We enrolled children younger than 24 months Methods—Body temperature, respiratory old, hospitalised with bronchiolitis, in the rate, oxygen saturation, and the need for period between December 1997 and May oxygen supplementation were recorded on 1999. Bronchiolitis was defined as an admission and daily throughout hospitali- acute viral respiratory syndrome, charac- sation. Complete blood count, erythrocyte terised by cough, tachypnoea (respiratory rate > 40/min), dyspnoea, and prolonged sedimentation rate, and assay for respira- 5 tory syncytial virus were performed on expirium with wheezing and/or crackles. admission. All children were examined Children with underlying bronchopulomonary daily for the appearance of AOM. The dysplasia and congenital heart disease were clinical course of children with bronchio- excluded. litis and AOM was compared to those Demographic information obtained on ad- without AOM. mission included gender, age, birth weight, and Results—AOM was diagnosed in 79/150 gestational age.
    [Show full text]